A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs TVB 2640 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors 3-V Biosciences; Sagimet Biosciences
- 05 Aug 2019 According to a 3-V Biosciences media release, the company has changed its name to Sagimet Biosciences.
- 11 Aug 2017 Status changed from active, no longer recruiting to completed.
- 31 Mar 2017 According to a 3-V Biosciences media release, the company will present data from this trial at the AACR annual meeting in Washington, D.C.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History